During the corresponding time, Silk Road Medical Inc recorded a revenue increase by 25.39 % year on year, sequentially revenue grew by 18.39 %. While revenue at the Silk Road Medical Inc 's corporate clients
Silk Road Medical Inc's Comment on Sales, Marketing and Customers
The company primarily serves customers in the medical field, focusing on the treatment of carotid artery disease through TCAR and related products. Its customer base includes physicians who perform TCAR procedures, with over 2,800 physicians trained and certified in the United States as of December 31, 2023. The company also targets fellows in medical teaching institutions for TCAR certification. Sales efforts are supported by marketing and practice development initiatives. The company plans to expand into international markets, specifically Japan and China, where it has obtained regulatory approvals and established exclusive distribution agreements. The Office of Medical Affairs oversees physician education, training, and compliance, requiring physicians to complete training before performing TCAR. Training is delivered through various formats, including in-person sessions, virtual programs, small group settings, and physician proctors.
Silk Road Medical Enhances TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUSSUNNYVALE, Calif., April 02, 2024 - Silk Road Medical, Inc. (Nasdaq: SILK), a leading company dedicated to reducing the risk of stroke and its detrimental consequences, has recently unveiled its latest innovation, the ENROUTE Transcarotid Neuroprotection System PLUS (NPS PLUS). The introduction of this advanced device adds significant enhancements to Silk Road Medical s TCAR portfolio, ensuring smoother arterial sheath insertion, improved flow precision, and a simplified preparation process for surgical teams. Most importantly, it guarantees unmatched neuroprotection during the TCAR procedure.TCAR (Transc...
Silk Road Medical Inc’s Comment on Sales, Marketing and Customers
The company primarily serves customers in the medical field, focusing on the treatment of carotid artery disease through TCAR and related products. Its customer base includes physicians who perform TCAR procedures, with over 2,800 physicians trained and certified in the United States as of December 31, 2023. The company also targets fellows in medical teaching institutions for TCAR certification. Sales efforts are supported by marketing and practice development initiatives. The company plans to expand into international markets, specifically Japan and China, where it has obtained regulatory approvals and established exclusive distribution agreements. The Office of Medical Affairs oversees physician education, training, and compliance, requiring physicians to complete training before performing TCAR. Training is delivered through various formats, including in-person sessions, virtual programs, small group settings, and physician proctors.
Sources:
Silk Road Medical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Silk Road Medical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Silk Road Medical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
